NCCN胰腺癌外科治疗指南解读

张太平; 肖剑春; 赵玉沛

NCCN胰腺癌外科治疗指南解读

中国医学科学院北京协和医院外科

详细信息

中图分类号: R735.9
计量
- 文章访问数: 3025
- HTML全文浏览量: 14
- PDF下载量: 820
- 被引次数: 0
出版历程
- 出版日期: 2010-05-20

Interpretation of NCCN guidelines for surgical treatment of pancreatic carcinoma

摘要

摘要: <正>胰腺癌是一种恶性程度极高的消化系统肿瘤,其发病率在全球范围内逐年上升。2009年美国胰腺癌新发病例数42 470例,死亡病例数35 240例,在恶性肿瘤死亡率中居第四位,5年生存率<5%[1]。我国胰腺癌发病率也有逐年增长的趋势。根治性手术切除是胰腺癌综合治疗的核心,也是胰腺癌患者获得长期生存的唯一希望,目前胰腺癌根治术后5年生存率可达15%～25%。近年来大的
- 胰腺肿瘤 /
- 诊疗准则
- pancreatic neoplasms /
- practice guideline

HTML全文

参考文献(44)

[1]Jemal A, Siegel R, Ward E, et al.Cancer statistics, 2009[J].CACancer J Clin, 2009, 59 (4) ∶225-249.

[2]Crist DW, Sitzmann JV, Cameron JL.Improved hospital morbidity, mortality, and survival after the Whipple procedure[J].Ann Surg, 1987, 206 (3) ∶358-365.

[3]Li D, Xie K, Wolff R, et al.Pancreatic cancer[J].Lancet, 2004, 363∶1049-1057.

[4]Bipat S, Phoa SS, van Delden OM, et al.Ultrasonography, com-puted tomography and magnetic resonance imaging for diagnosis anddetermining resectability of pancreatic adenocarcinoma:a meta-a-nalysis[J].J Comput Assist Tomogr, 2005, 29 (4) ∶438-445.

[5]National Comprehensive Cancer Network (NCCN) Clinical PracticeGuideline in Oncology for Pancreatic Adenocarcinoma V[S].1.2009.

[6]中华医学会外科学分会胰腺外科学组.胰腺癌诊治指南[J].中国实用外科杂志, 2007, 27 (9) ∶671-673.

[7]赵玉沛, 张太平.重视交界性可切除胰腺癌的处理[J].中国普外基础与临床杂志, 2009, 16 (8) ∶597-604.

[8]Katz MH, Pisters PW, Evans DB, et al.Borderline resectable pan-creatic cancer:the importance of this emerging stage of disease[J].J Am Coll Surg, 2008, 206 (5) ∶833-846.

[9]Evans DB, Varadhachary GR, Crane CH, et al.Preoperative gem-citabine-based chemoradiation for patients with resectable adeno-carcinoma of the pancreatic head[J].J Clin Oncol, 2008, 26∶3496-3502.

[10]Gillen S, Schuster T, Meyer ZC, et al.Preoperative/neoadjuvanttherapy in pancreatic cancer:a systematic review and meta-analy-sis of response and resection percentages[J].PLoS Med, 2010, 7 (4) ∶e1000267.

[11]McClaine RJ, Lowy AM, Sussman JJ, et al.Neoadjuvant therapymay lead to successful surgical resection and improved survival inpatients with borderline resectable pancreatic cancer[J].HPB (Oxford) , 2010, 12 (1) ∶73-79.

[12]Landry J, Catalano PJ, Staley C, et al.Randomized phase II studyof gemcitabine plus radiotherapy versus gemcitabine, 5-fluoroura-cil, and cisplatin followed by radiotherapy and 5-fluorouracil forpatients with locally advanced, potentially resectable pancreatic ad-enocarcinoma[J].J Surg Oncol, 2010, 101 (7) ∶587-592.

[13]Turrini O, Viret F, Moureau-Zabotto L, et al.Neoadjuvant che-moradiation and pancreaticoduodenectomy for initially locally ad-vanced head pancreatic adenocarcinoma[J].Eur J Surg Oncol, 2009, 35 (12) ∶1306-1311.

[14]Klinkenbijl JH, Jeekel J, Schmitz PI, et al.Carcinoma of the pan-creas and periampullary region:palliation versus cure[J].Br JSurg, 1993, 80∶1575-1578.

[15]Trede M, Schwall G.The complications of pancreatectomy[J].Ann Surg, 1988, 207∶39-47.

[16]Kimmings AN, van Deventer SJ, Obertop H, et al.Endotoxin, cy-tokines, and endotoxin binding proteins in obstructive jaundice andafter preoperative biliary drainage[J].Gut, 2000, 46∶725-731.

[17]Wang Q, Gurusamy KS, Lin H, et al.Preoperative biliary drainagefor obstructive jaundice[J].Cochrane Database Syst Rev, 2008, 3∶CD005444-CD005444.

[18]Sewnath ME, Karsten TM, Prins MH, et al.A meta-analysis onthe efficacy of preoperative biliary drainage for tumors causing ob-structive jaundice[J].Ann Surg, 2002, 236∶17-27.

[19]Hidalgo M.Pancreatic cancer[J].N Engl J Med, 2010, 362 (17) ∶1605-1617.

[20]van der Gaag NA, Rauws EA, van Eijck CH, et al.Preoperativebiliary drainage for cancer of the head of the pancreas[J].N Engl JMed, 2010, 362 (2) ∶129-137.

[21]Seiler CA, W agnerM, Bachmann T, et al.Random ized clinicaltrial of pylorus reserving duodenopancreatectomy versus classicalWhipple resection long term results[J].Br J Surg, 2005, 92 (5) ∶547-556.

[22]Wenger FA, Jacobi CA, Haubold K, et al.Gastrointestinal qualityof life after duodenopancreatectomy in pancreatic carcinoma.Pre-liminary results of a prospective randomized study:pancreatoduode-nectomy or pylorus-preserving pancreatoduodenectomy[J].Chiru-rg, 1999, 70 (12) ∶1454-1459.

[23]Srinarmwong C, Luechakiettisak P, Prasitvilai W.Standard whip-ple's operation versus pylorus preserving pancreaticoduodenectomy:arandomized controlled trial study[J].J Med Assoc Thai, 2008, 91 (5) ∶693-698.

[24]Lin PW, Shan YS, Lin YJ, et al.Pancreaticoduodenectomy forpancreatic head cancer:PPPD versus Whipple procedure[J].Hep-atogastroenterology, 2005, 52 (65) ∶1601-1604.

[25]Kurosaki I, Hatakeyama K.Clinical and surgical Factors influen-cing delayed gastric emp tying after PPPD[J].Hepatogastroenterol-ogy, 2005, 52 (61) ∶143-148.

[26]Tran KT, Smeenk HG, van Eijck CH, et al.Pylorus preservingpancreaticoduodenectomy versus standard Whipple procedure:aprospective, randomized, multicenter analysis of 170 patients withpancreatic and periampullary tumors[J].Ann Surg, 2004, 240 (5) ∶738-745.

[27]Yeo CJ, Cameron JL, Lillemoe KD, et al.Pancreaticoduodenecto-my with or without distal gastrectomy and extended retroperitoneallymphadenectomy for periampullary adenocarcinoma, part 2:ran-domized controlled trial evaluating survival, morbidity, and mortali-ty[J].Ann Surg, 2002, 236 (3) ∶355-368.

[28]Riall TS, Cameron JL, Lillemoe KD, et al.Pancreaticoduodenecto-my with or without distal gastrectomy and extended retroperitoneallymphadenectomy for periampullary adenocarcinoma-part 3:up-date on 5-year survival[J].J Gastrointest Surg, 2005, 9 (9) ∶1191-1206.

[29]Dineen SP, Roland CL, Schwarz RE.Pancreatoduodenectomy withor without pyloric preservation:a clinical outcomes comparison[J].HPB Surg, 2008, 2008∶1-8.

[30]Tani M, Kawai M, Hirono S, et al.Pylorus-preserving pancreati-coduodenectomy versus conventional pancreaticoduodenectomy forpancreatic adenocarcinoma[J].Surg Today, 2009, 39 (3) ∶219-224.

[31]Yeo CJ, Cameron JL, Sohn TA, et al.Pancreaticoduodenectomywith or without extended retroperitoneal lymphadenectomy for peri-ampullary adenocarcinoma:comparison of morbidity and mortalityand short-term outcome[J].Ann Surg, 1999, 229 (5) ∶613-622.

[32]Farnell MB, Pearson RK, Sarr MG, et al.A prospective random-ized trial comparing standard pancreatoduodenectomy with pancre-atoduodenectomy with extended lymphadenectomy in resectable pan-creatic head adenocarcinoma[J].Surgery, 2005, 138 (4) ∶618-628.

[33]Farnell MB, Aranha GV, Nimura Y, et al.The role of extendedlymphadenectomy for adenocarcinoma of the head of the pancreas:strength of the evidence[J].J Gastrointest Surg, 2008, 12 (4) ∶651-656.

[34]Yamada S, Fujii T, Sugimoto H, et al.Pancreatic cancer with dis-tant metastases:a contraindication for radical surgery?[J].Hepa-togastroenterology, 2009, 56 (91-92) ∶881-885.

[35]Müller SA, Hartel M, Mehrabi A, et al.Vascular resection in pan-creatic cancer surgery:survival determinants[J].J GastrointestSurg, 2009, 13 (4) ∶784-792.

[36]Tseng JF, Raut CP, Lee JE, et al.Pancreaticoduodenectomy withvascular resection:margin status and survival duration[J].J Gas-trointest Surg, 2004, 8 (8) ∶935-949.

[37]Chua TC, Saxena A.Extended Pancreaticoduodenectomy with Vas-cular Resection for Pancreatic Cancer:A Systematic Review[J].JGastrointest Surg, 2010 Apr 9.

[38]Schniewind B, Bestmann B, Kurdow R, et al.Bypass surgery ver-sus palliative pancreaticoduodenectomy in patients with advancedductal adenocarcinoma of the pancreatic head, with an emphasis onquality of life analyses[J].Ann Surg Oncol, 2006, 13 (11) ∶1403-1411.

[39]Kninger J, Wente MN, Müller-Stich BP, et al.R2 resection inpancreatic cancer-does it make sense?[J].Langenbecks ArchSurg, 2008, 393 (6) ∶929-934.

[40]Artifon EL, Sakai P, Cunha JE, et al.Surgery or endoscopy for pal-liation of biliary obstruction due to metastatic pancreatic cancer[J].Am J Gastroenterol, 2006, 101 (9) ∶2031-2037.

[41]Kruse EJ.Palliation in pancreatic cancer[J].Surg Clin North Am, 2010, 90 (2) ∶355-364.

[42]Larssen L, Medhus AW, Hauge T.Treatment of malignant gastricoutlet obstruction with stents:an evaluation of the reported variablesfor clinical outcome[J].BMC Gastroenterol, 2009, 9∶45.

[43]Jeurnink SM, Polinder S, Steyerberg EW, et al.Cost comparison ofgastrojejunostomy versus duodenal stent placement for malignantgastric outlet obstruction[J].J Gastroenterol, 2010, 45 (5) ∶537-543.

[44]Hüser N, Michalski CW, Schuster T, et al.Systematic review andmeta-analysis of prophylactic gastroenterostomy for unresectableadvanced pancreatic cancer[J].Br J Surg, 2009, 96 (7) ∶711-719.

施引文献

资源附件(0)

访问统计